Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter & Fiscal Year 2019 & Provides Initial 2020 Outlook
January 13 2020 - 07:30AM
Business Wire
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose
monitoring (“CGM”), today reported that it expects preliminary,
unaudited revenue for the fourth quarter ended December 31, 2019 to
be approximately $457 million, an increase of 35% over the fourth
quarter of 2018. U.S. revenue is expected to be approximately $373
million, representing growth of 33% over the fourth quarter of
2018. International revenue is expected to be approximately $84
million, an increase of 47% over the fourth quarter of 2018.
For fiscal 2019, total preliminary, unaudited revenue is
expected to be approximately $1.470 billion, an increase of more
than 42% over 2018.
“2019 was another amazing year for Dexcom, demonstrating the
growing awareness of real-time CGM for managing diabetes and
customer excitement for our G6 platform. This was the second
consecutive year of greater than 40% growth, far exceeding our own
expectations and a strong accomplishment for a company of our
size,” said Kevin Sayer, Dexcom’s Chairman, President and CEO. “We
are hitting the ground running in 2020 and believe we are well
positioned to continue our growth momentum.”
2020 Outlook
For 2020, Dexcom currently anticipates total revenue of
approximately $1.725 billion to $1.775 billion, representing
expected growth of approximately 17% to 21% over 2019. This growth
outlook is driven by strong growth in sensor volumes, continued
international expansion, shifting channel mix and overall market
dynamics.
Dexcom will provide further details related to its 2020
financial expectations on the fourth quarter earnings call.
Fourth Quarter 2019 Financial Results Conference Call
Dexcom will report its audited full fourth quarter and fiscal
2019 financial results on Thursday, February 13, 2020 after the
close of market. Management is currently scheduled to host a
conference call at 4:30 p.m. (Eastern Time) that day. More details
will be provided later.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is
developing and marketing continuous glucose monitoring systems for
ambulatory use by people with diabetes and by healthcare providers
for the treatment of people with diabetes.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking statements that are
not purely historical regarding Dexcom’s or its management’s
intentions, beliefs, expectations and strategies for the future,
including those related to Dexcom’s expected revenue for the fourth
quarter of and the full fiscal year 2019, estimated revenue for
fiscal 2020, expected 2020 growth in sensor volumes and
international revenue. All forward-looking statements included in
this press release are made as of the date of this release, based
on information currently available to Dexcom, deal with future
events, are subject to various risks and uncertainties, and actual
results could differ materially from those anticipated in those
forward-looking statements. The risks and uncertainties that may
cause actual results to differ materially from Dexcom’s current
expectations are more fully described in Dexcom’s Annual Report on
Form 10-K for the period ended December 31, 2018, as filed with the
Securities and Exchange Commission on February 21, 2019. Except as
required by law, Dexcom assumes no obligation to update any such
forward-looking statement after the date of this report or to
conform these forward-looking statements to actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200113005298/en/
Steven R. Pacelli Executive Vice President, Strategy and
Corporate Development (858) 200-0200 www.dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Feb 2024 to Mar 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2023 to Mar 2024